Progressive Ataxia and Weakness Disorders Market Report 2024

Where is the largest and fastest growing market for progressive ataxia and weakness disorders? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The progressive ataxia and weakness disorders market size has grown rapidly in recent years. It will grow from $31.33 billion in 2023 to $34.72 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the past can be linked to heightened awareness and diagnosis, advancements in genetic research, increased government funding, rising healthcare expenditures, and a surge in alcohol and drug use.

The progressive ataxia and weakness disorders market size is expected to see rapid growth in the next few years. It will grow to $52.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated growth in the future is due to the growing incidence of neurological disorders, the increasing prevalence of chronic diseases, broader insurance coverage, and an aging population. Key trends expected during this period include technological progress, advancements in genetic testing and gene therapy, personalized medicine, and the wider adoption of telemedicine.

The increasing prevalence of neurological disorders is expected to drive growth in the market for progressive ataxia and weakness disorders. Neurological disorders affect the central and peripheral nervous systems, encompassing the brain, spinal cord, nerves, and neuromuscular junctions, among others. This rise in prevalence is attributed to factors such as an aging population, genetic predisposition, and infectious diseases. Progressive ataxia and weakness disorders play a crucial role in neurology, guiding diagnosis, treatment, and research efforts aimed at improving outcomes and quality of life for those affected by these challenging conditions. For example, the European Brain Council reported in April 2022 that the number of Europeans with dementia, a neurological condition, was 10.5 million in 2022, projected to increase to 18.7 million by 2050. Therefore, the growing prevalence of neurological disorders is a significant driver for the progressive ataxia and weakness disorders market.

Key companies in the progressive ataxia and weakness disorders market are focused on developing innovative products, such as oral medications for treating specific disorders such as Friedreich's ataxia in adults and adolescents aged 16 years and older. Oral medications are typically administered in tablet, capsule, or liquid form for convenient ingestion. For instance, Biogen Inc., a U.S.-based biotechnology company, announced in February 2024 that SKYCLARYS (omaveloxolone) had received approval from the European Commission for treating Friedreich's ataxia. SKYCLARYS acts by activating the Nrf2 pathway to address oxidative stress and mitochondrial dysfunction underlying Friedreich's ataxia. The medication is taken orally without food and has demonstrated efficacy in clinical trials by improving symptoms and slowing disease progression. Common side effects include elevated liver enzymes, headaches, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pain.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition was aimed at enhancing Pfizer's position in the pharmaceutical market, particularly in neurology, by expanding its portfolio with Biohaven's investigational drug troriluzole and other treatments for progressive ataxia and weakness disorders. Biohaven Pharmaceutical Holding Company Ltd. specializes in developing therapies for neurological conditions, contributing to Pfizer's capabilities in advancing treatments for these challenging disorders and other therapeutic areas.

Major companies operating in the progressive ataxia and weakness disorders market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Banner Health, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Kissei Pharmaceutical Co. Ltd., Biohaven Pharmaceutical Holding Company Ltd., Design Therapeutics Inc., Anavex Life Sciences Corp., Larimar Therapeutics Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Capsida Biotherapeutics Inc., Retrotope Inc., Taysha Gene Therapies Inc., CRISPR Therapeutics AG.

North America was the largest region in the progressive ataxia and weakness disorders market in 2023. The regions covered in the progressive ataxia and weakness disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the progressive ataxia and weakness disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Progressive ataxia and weakness disorders encompass a range of medical conditions marked by a gradual decline in coordination and muscle strength. These conditions greatly affect a person's quality of life and often necessitate a multidisciplinary approach for accurate diagnosis and effective management.

The primary categories of progressive ataxia and weakness disorders are progressive ataxia and progressive weakness disorders. Progressive ataxia involves a gradual loss of muscle coordination and balance, resulting from degenerative or genetic conditions that impact the cerebellum or other areas of the nervous system. This field includes various technologies, such as small molecules and monoclonal antibodies, which are distributed through multiple channels such as retail pharmacies, hospital pharmacies, and online pharmacies. These treatments are utilized in diverse settings, including hospitals and clinics.

The progressive ataxia and weakness disorders market research report is one of a series of new reports that provides progressive ataxia and weakness disorders market statistics, including progressive ataxia and weakness disorders industry global market size, regional shares, competitors with a progressive ataxia and weakness disorders market share, detailed progressive ataxia and weakness disorders market segments, market trends and opportunities, and any further data you may need to thrive in the progressive ataxia and weakness disorders industry. This progressive ataxia and weakness disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The progressive ataxia and weakness disorders market consists of revenues earned by entities by providing services such as diagnostic testing, treatment planning, specialized care, and research and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The progressive ataxia and weakness disorders market also includes sales of assistive devices, therapeutic equipment, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.